Brokerages expect Biopharmx Corp (NYSE:BPMX) to post $20,000.00 in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Biopharmx Corp’s earnings. The highest sales estimate is $30,000.00 and the lowest is $10,000.00. Biopharmx Corp also posted sales of $20,000.00 in the same quarter last year. The firm is scheduled to report its next earnings results on Monday, September 11th.

According to Zacks, analysts expect that Biopharmx Corp will report full year sales of $20,000.00 for the current year, with estimates ranging from $30,000.00 to $590,000.00. For the next year, analysts anticipate that the business will report sales of $5.07 million per share, with estimates ranging from $50,000.00 to $15.00 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Biopharmx Corp.

Separately, ValuEngine raised Biopharmx Corp from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 24th.

ILLEGAL ACTIVITY WARNING: “Brokerages Expect Biopharmx Corp (BPMX) Will Announce Quarterly Sales of $20,000.00” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/21/brokerages-expect-biopharmx-corp-bpmx-will-announce-quarterly-sales-of-20000-00.html.

Biopharmx Corp (NYSE:BPMX) opened at 0.2944 on Monday. The stock’s 50 day moving average price is $0.38 and its 200-day moving average price is $0.50. The stock’s market capitalization is $21.82 million. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $1.22.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.